Kenvue Inc. (NYSE:KVUE – Get Free Report) has received an average rating of “Hold” from the eighteen analysts that are covering the company, Marketbeat.com reports. Twelve analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $20.2333.
A number of equities analysts have issued reports on the stock. Bank of America cut their price objective on shares of Kenvue from $25.00 to $21.00 and set a “buy” rating on the stock in a report on Wednesday, October 8th. Evercore ISI set a $18.00 price objective on shares of Kenvue in a research note on Tuesday, October 28th. Jefferies Financial Group cut their target price on Kenvue from $25.00 to $23.00 and set a “buy” rating on the stock in a research note on Monday, October 27th. Edward Jones downgraded Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 3rd. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Kenvue in a research note on Friday, January 9th.
Read Our Latest Analysis on Kenvue
Insider Activity at Kenvue
Institutional Trading of Kenvue
Hedge funds have recently made changes to their positions in the company. Cornerstone Planning Group LLC increased its holdings in Kenvue by 705.2% in the 3rd quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock worth $25,000 after acquiring an additional 1,361 shares during the last quarter. NBT Bank N A NY increased its stake in shares of Kenvue by 180.3% in the third quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock worth $25,000 after purchasing an additional 1,006 shares in the last quarter. Salomon & Ludwin LLC bought a new stake in shares of Kenvue in the third quarter valued at approximately $25,000. Trust Co. of Vermont lifted its stake in shares of Kenvue by 266.8% during the 2nd quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock valued at $33,000 after buying an additional 1,150 shares in the last quarter. Finally, Golden State Wealth Management LLC lifted its stake in shares of Kenvue by 150.1% during the 3rd quarter. Golden State Wealth Management LLC now owns 1,983 shares of the company’s stock valued at $32,000 after buying an additional 1,190 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.
Kenvue Price Performance
Shares of NYSE KVUE opened at $17.36 on Thursday. The stock has a market cap of $33.25 billion, a price-to-earnings ratio of 23.14 and a beta of 0.60. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 0.98. Kenvue has a fifty-two week low of $14.02 and a fifty-two week high of $25.17. The firm’s 50-day simple moving average is $17.13 and its 200 day simple moving average is $18.08.
Kenvue (NYSE:KVUE – Get Free Report) last issued its quarterly earnings data on Monday, November 3rd. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.27 by $0.01. The firm had revenue of $3.76 billion during the quarter, compared to the consensus estimate of $3.83 billion. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The company’s quarterly revenue was down 3.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.28 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, research analysts anticipate that Kenvue will post 1.14 earnings per share for the current fiscal year.
Kenvue Dividend Announcement
The business also recently announced a dividend, which will be paid on Wednesday, February 25th. Stockholders of record on Wednesday, February 11th will be given a dividend of $0.2075 per share. The ex-dividend date of this dividend is Wednesday, February 11th. Kenvue’s dividend payout ratio is currently 110.67%.
About Kenvue
Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.
The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.
Read More
- Five stocks we like better than Kenvue
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Do not delete, read immediately
- NEW LAW: Congress Approves Setup For Digital Dollar?
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- A U.S. “birthright” claim worth trillions – activated quietly
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.
